



**Item 8.01** Other Events

On October 22, 2008, Antigenics Inc. announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) requesting approval for Oncophage® in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision.

The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01** Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated October 22, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: October 22, 2008 By: /s/ Garo H. Armen

Garo H. Armen  
Chairman and CEO

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated October 22, 2008